Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah E Pinder

Showing results (21-30 of 149) with videos related to

Pageof 15
Sort By:
Breast Cancer Research and Treatment|August 10, 2015
Selection and evolution in the genomic landscape of copy number alterations in ductal carcinoma in situ (DCIS) and its progression to invasive carcinoma of ductal/no special type: a meta-analysisSwapnil Ulhas Rane, Hasan Mirza, Anita Grigoriadis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Reply to R.F. Sweis et alPeter Schmid, Sarah E Pinder, Arnie Purushotham, et al.
Human Pathology|October 24, 2012
Synchronous ductal carcinoma in situ of the breast and within epithelial inclusions in an ipsilateral sentinel lymph nodeVirginia L Fitzpatrick-Swallow, Heidi Helin, Paul Cane, et al.
Journal of Therapeutic Ultrasound|January 21, 2016
A review of ablative techniques in the treatment of breast fibroadenomataMirjam C L Peek, Muneer Ahmed, Sarah E Pinder, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2014
Addendum to BASOII Trial reportDavid A L Morgan, Tom Bates, Stephen W Duffy, et al.
Breast (Edinburgh, Scotland)|January 30, 2013
Challenges in the management of pleomorphic lobular carcinoma in situ of the breastYazan A Masannat, Salena K Bains, Sarah E Pinder, et al.
Genome Biology|August 9, 2007
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancerAndrew E Teschendorff, Ahmad Miremadi, Sarah E Pinder, et al.
International Journal of Cancer|May 19, 2005
Total loss of MHC class I is an independent indicator of good prognosis in breast cancerZahra Madjd, Ian Spendlove, Sarah E Pinder, et al.
British Journal of Cancer|February 16, 2021
Reply to "Comment on: Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project"Abeer M Shaaban, Bridget Hilton, Karen Clements, et al.
Journal of Clinical Pathology|July 21, 2012
Current issues in diagnostic breast pathologyRosemary A Walker, Andy Hanby, Sarah E Pinder, et al.
Pageof 15

Showing results (21-30 of 149) with videos related to

Sort By:
Pageof 15
Breast Cancer Research and Treatment|August 10, 2015
Selection and evolution in the genomic landscape of copy number alterations in ductal carcinoma in situ (DCIS) and its progression to invasive carcinoma of ductal/no special type: a meta-analysisSwapnil Ulhas Rane, Hasan Mirza, Anita Grigoriadis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Reply to R.F. Sweis et alPeter Schmid, Sarah E Pinder, Arnie Purushotham, et al.
Human Pathology|October 24, 2012
Synchronous ductal carcinoma in situ of the breast and within epithelial inclusions in an ipsilateral sentinel lymph nodeVirginia L Fitzpatrick-Swallow, Heidi Helin, Paul Cane, et al.
Journal of Therapeutic Ultrasound|January 21, 2016
A review of ablative techniques in the treatment of breast fibroadenomataMirjam C L Peek, Muneer Ahmed, Sarah E Pinder, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2014
Addendum to BASOII Trial reportDavid A L Morgan, Tom Bates, Stephen W Duffy, et al.
Breast (Edinburgh, Scotland)|January 30, 2013
Challenges in the management of pleomorphic lobular carcinoma in situ of the breastYazan A Masannat, Salena K Bains, Sarah E Pinder, et al.
Genome Biology|August 9, 2007
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancerAndrew E Teschendorff, Ahmad Miremadi, Sarah E Pinder, et al.
International Journal of Cancer|May 19, 2005
Total loss of MHC class I is an independent indicator of good prognosis in breast cancerZahra Madjd, Ian Spendlove, Sarah E Pinder, et al.
British Journal of Cancer|February 16, 2021
Reply to "Comment on: Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project"Abeer M Shaaban, Bridget Hilton, Karen Clements, et al.
Journal of Clinical Pathology|July 21, 2012
Current issues in diagnostic breast pathologyRosemary A Walker, Andy Hanby, Sarah E Pinder, et al.
Pageof 15